Safety and efficacy outcomes in patients receiving drug-resistant TB treatment including concomitant Bedaquiline (BDQ) and Delamanid: A retrospective cohort study
Latest Information Update: 28 Oct 2020
Price :
$35 *
At a glance
- Drugs Bedaquiline (Primary) ; Delamanid (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- 28 Oct 2020 New trial record
- 20 Oct 2020 Results published in the Clinical Infectious Diseases